The latest report by IMARC Group titled, “Generic Oncology Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, finds that the global generic oncology drug market reached a value of more than US$ 18 Billion in 2016, growing at a CAGR of around 12% during 2009-2016. Generic drugs account for almost 80% of the total prescriptions across different medical specialties. After branded drugs go off-patent, manufacturers in the pharmaceuticals industry secure the right to develop and sell a generic version of those drugs. Generic drugs carry the same functional properties as their branded counterparts. Additionally, these are available in the market at a much cheaper price; almost one-tenth of the branded drug. Currently, there is a high demand for generic oncology drugs as a result of a growth in the number of cancer patients across the globe. Some of most commonly diagnosed cancers around the world include lung, breast, and colorectum cancers.
Highlights of the global generic oncology drug market:
- The market is driven by active participation of the healthcare organisations.
- The market is bifurcated broadly as imatinib tablets and paclitaxel injectables.
- The market is expected to reach a value of more than US$ 32 Billion by 2022.
Request a free sample copy of the report: http://www.imarcgroup.com/request?type=report&id=545&flag=B
According to a research, in 2015 nearly 15 Million patients were diagnosed with cancer, among which more than 8 Million lost their lives to it. The major causes of the dissemination of cancer on such a wide scale are lack of awareness and high costs of treatment. Most patients, particularly in the developing regions, do not have access to expensive drugs and therapies that are required to cure cancer. Due to this, manufacturing of generic oncology drugs is promoted by both, government and non-government health organisations in order to provide treatment to the maximum number of people at affordable rate. Further, the market is expected to reach a value of more than US$ 32 Billion by 2022.
The market is segmented on the basis of product type including imatinib tablet and paclitaxel injectable. The market is also segmented on the basis of key regions. Some of the major markets for generic oncology drugs are the USA, China, Brazil, Germany, and France. An analysis of the competitive landscape provides the details of the key players operative in the market. Some of the major players are Teva Pharmaceuticals, Novartis-Sandoz, Mylan, Freseunis, and Hospira.
Click here for the summary of the report and table of contents: http://www.imarcgroup.com/generic-oncology-drug-manufacturing-plant
The report by IMARC Group has examined the global generic oncology drug market on the basis of:
Product Type:
- Imatinib Tablet
- Paclitaxel Injectable
Key Regions:
- USA
- China
- Brazil
- Germany
- France
Key Players:
- Teva Pharmaceuticals
- Novartis-Sandoz
- Mylan
- Freseunis
- Hospira
Browse related reports:
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Media Contact
Company Name: IMARC Group
Contact Person: Jim Clarke
Email:Send Email
Phone: +1-631-791-1145
Country: United States
Website: http://www.imarcgroup.com/
